newsfilter
← Latest News
Business Wire·

Equillium Maintains Rights to Itolizumab Following Ono Partnership

EQ

Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study